Clinical application of Dapagliflozin in patients with type 2 diabetes mellitus and hypertension
HAO Yan-hong1 WU Qing1 LI Yun2 WANG Ying-li1 ZHANG Ying1 LUO Ya-hui1 LIU Yan-dong1 LI Yin1
1.Department of Endocrinology,Beijing Jiangong Hospital,Beijing 100054,China;
2.School of Public Health,North China University of Science and Technology,Hebei Province,Tangshan 063210,China
Abstract：Objective To explore the clinical application of Dapagliflozin in patients with type 2 diabetes mellitus and hypertension.Methods A total of 285 patients with type 2 diabetes mellitus and hypertension were enrolled as the research objects from January 2018 to December 2019 in the Department of Endocrinology,Beijing Jiangong Hospital and were divided into the Dapagliflozin group(142 cases)and Sitagliptin group(143 cases)according to the random number table method.Patients in the Dapagliflozin group were treated with Metformin Hydrochloride Tablets+Dapagliflozin,and patients in the Sitagliptin group were treated with Metformin Hydrochloride Tablets+Sitagliptin.After 24 weeks of treatment,changes of glycosylated hemoglobin(HbA1c),fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PG),systolic blood pressure(SBP),diastolic blood pressure(DBP)and body mass index(BMI)of patients between the two groups were compared.The occurrence of hypoglycemia,hypotension and urinary tract infection was compared between the two groups.Results Finally,133 cases were included in the Dapagliflozin group and 133 cases in the Sitagliptin group.After treatment,the HbA1c and 2 h PG of patients in the Dapagliflozin group were higher than those in the Sitagliptin group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in FBG between the two groups after treatment(P>0.05).The HbA1c,FBG,and 2 h PG of the two groups after treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).The SBP and DBP of patients in the Dapagliflozin group after treatment were lower than those in the Sitagliptin group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in BMI between the two groups after treatment(P>0.05).The SBP and DBP of the two groups after treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).The BMI in the Dapagliflozin group after treatment was lower than that before treatment in this group,and the difference was statistically significant(P<0.05).After treatment,the incidence of urinary tract infection in the Dapagliflozin group was higher than that in the Sitagliptin group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of hypoglycemia between the two groups after treatment(P>0.05).There was no hypotension in the two groups.Conclusion When Dapagliflozin is used in patients with type 2 diabetes and hypertension,it is easy to cause urinary tract infections.But its hypoglycemic effect is definite,especially its hypotensive and weight reduction effect is obvious and there are fewer hypoglycemia and hypotension events.As a whole,it is clinically relatively safe.
Wiviott SD，Raz I，Bonaca MP，et al.Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med，2019，380（4）：347-357.
[6]
Wiviott SD，Raz I，Bonaca MP，et al.The design and rationale for the Dapagliflozin Effect on Cardiovascular Events（DECLARE）TIMI 58 Trial[J].Am Heart J，2018，200：83-89.
[7]
Wilding JPH，Rigney U，Blak BT，et al.Glycaemic，weight，and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus[J].Diabetes Res Clin Pract，2019，155：107 791.
京公网安备 11010502046607号